RxDoctor Payments Data

Scott Warren, DPM

Foot Surgery · Pennington, NJNPI 1396782397

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 21 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Smith+Nephew at 39.8% of the total. 2025 is the largest year on record at $192, 2.3 times the $83 reported in 2019. That places this record below the midpoint for foot surgery clinicians in NJ, where the typical reported total is $943.

$462in general payments, 2019–2025

Across 21 payments — averaging $22.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$184
  • Kerecis Limited$124
  • Medartis Inc.$65
  • Tactile Systems Technology Inc$28
  • Solventum Corporation$21
  • Integra Lifesciences Corporation$18
  • plus $22 from 2 others

What the payments were for

  • Food & beverage$462100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$462 in reported general payments places this provider in the 35th percentile of 59 foot surgery providers in New Jersey.

See all foot surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$99,724
Medicare patients
431
Services billed
1,400

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.34$18,077
Ketoconazole22$492
Gabapentin12$293
Mupirocin34$218
Doxycycline Hyclate20$170
Hydrocortisone11$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$184$18,07734 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 59 foot surgery providers in New Jersey.

Other foot surgery in Pennington

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →